Please assess the completion status of the following clinical trial:

Trial Title: A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older.~* Histologically confirmed, relapsed or refractory, follicular B-cell non-Hodgkin lymphoma (NHL) (follicular lymphoma) Grade 1, 2, and 3a.~* Ineligible for hematopoietic stem cell transplant.~* Must have been treated with at least 2 prior systemic therapies.~* Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures \> 1.5 cm in the longest dimension and ≥ 1.0 cm in the longest perpendicular dimension as assessed by computed tomography or magnetic resonance imaging.~* Must be willing to undergo an incisional, excisional, or core needle lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.~Exclusion Criteria:~* Known histological transformation from indolent NHL to diffuse large B-cell lymphoma.~* History of central nervous system lymphoma (either primary or metastatic).~* Prior treatment with idelalisib, other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors, or a pan-PI3K inhibitor.~* Prior treatment with a Bruton's tyrosine kinase inhibitor (eg, ibrutinib).~* Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of study treatment administration.~* Active graft-versus-host disease.~* Participants positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for hepatitis B virus-deoxyribonucleic acid (HBV-DNA). Participants positive for anti-hepatitis C virus (HCV) antibody will be eligible if they are negative for HCV-ribonucleic acid (RNA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A: Parsaclisib 20 mg QD for 8 Weeks Followed by 20 mg QW (Type: EXPERIMENTAL): Participants received parsaclisib 20 mg once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to approximately 52 weeks.
- Treatment B: Parsaclisib 20 mg QD for 8 Weeks Followed by 2.5 mg QD (Type: EXPERIMENTAL): Participants received parsaclisib 20 mg QD for 8 weeks followed by 2.5 mg QD for up to approximately 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).